Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
10 May 2021

Telix begins Phase III prostate cancer treatment trial

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients. The trial initiation comes after approval…

10 May 2021

AstraZeneca’s combination therapy shows overall survival benefit in NSCLC

A human monoclonal antibody (mAb), Imfinzi attaches to programmed death-ligand 1 (PD-L1) while Tremelimumab, also a human mAb, hinders cytotoxic T-lymphocyte-associated protein 4’s (CTLA-4) activity. The randomised, open-label, multi-centre, global Phase III POSEIDON trial…